| Literature DB >> 35547819 |
Yidan Tang1, Changliang Liu1, Tao Zhu1, Hai Chen2, Yalan Sun1, Xueying Zhang1, Qi Zhao1, Jiahui Wu1, Xuejie Fei3, Shixin Ye4, Chan Chen1.
Abstract
Background: Chronic neuropathic pain is commonly associated with memory loss, which increases the risk of dementia, lowers life quality and spending. On the other hand, the molecular processes are unknown, and effective therapies have yet to be discovered. Long non-coding RNAs (lncRNAs) are emerging potential therapeutic targets for chronic pain, but their role in chronic pain-induced memory impairment is unknown.Entities:
Keywords: ATF3; RNA-seq; ferroptosis; memory impairment; pain
Year: 2022 PMID: 35547819 PMCID: PMC9082550 DOI: 10.3389/fcell.2022.843297
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
The total reads and mapping ratio for sham and CCI with memory impairment groups by RNA-Seq.
| Sample | Total raw reads (Mb) | Total clean reads (Mb) | Clean reads Q30 (30%) | Valid bases (%) | Total mapped reads (%) |
|---|---|---|---|---|---|
| Sham 1 | 94.89 | 93.35 | 93.33 | 92.78 | 96.61 |
| Sham 2 | 99.48 | 97.87 | 93.32 | 93.03 | 96.52 |
| Sham 3 | 97.62 | 96 | 93.31 | 92.22 | 96.46 |
| CCI 1 | 95.85 | 94.25 | 93.01 | 92.92 | 96.42 |
| CCI 2 | 94.85 | 93.36 | 93.13 | 92.84 | 96.4 |
| CCI 3 | 96.6 | 94.98 | 93.38 | 92.66 | 96.33 |
All primers sequence for qRT-PCR analysis.
| Gene name | Forward | Reverse |
|---|---|---|
| 18sRNA | GACACGGACAGGATTGACAG | GCTCCACCAACTAAGAACGG |
| NFS1 | GGAGGCCCTACAAAGTGGAG | CCATCTCCCAGAGAGGACTCA |
| CARTPT | GGACATCTACTCTGCCGTGG | CAATCTGCAACACAGCGCC |
| APH1B | GGGTACCATGACAGCGCC | CCAGCGTCATGAAAGCTGAATTA |
| NDUFA10 | GCCTTGAGGTTGCTGAGACT | GATGGAACGCTCCAAGACCA |
| MRPL53 | GTGGAGTCAACAAGGACCTTTC | TGGTTAAGCAGTGAGAAAGAAAAA |
| ATF3 | CGACCAACCCGCGCTC | CTCTCCAGTTTCTCTGACTCCTTCT |
| CBLN1 | AGACCATCCAGGTGAGCCT | AGGAACCATAATGACAAGGCA |
| MT1 | CTGCTGCCCTCAGGTGTAAA | ATGCTCGGTAGAAAACGGGG |
| OXTR | CTGCTGTGTCGTCTGGTCAA | GCTTGACACTACTGACCCGT |
| LOC102549072 | GTCCTTTCAGTCTTGCGGGA | CCTAAGTCCTCCGACCCAGA |
| LOC103693876 | GTAGAACCCACACGCAGGAA | AGAAGCAGGCAAATTCCCGA |
| LOC102550954 | ACCATGGTCAATGGCACTGT | TCTGGAACCAGGACTGACCA |
| LOC108351425 | TGGGAACCAGAACCCAAATGT | TGGCAGTGATTGGTATTGAGG |
| LOC103691475 | TGAGGGGGTTAATCAGGTGT | TGCACTCTTTTGGTGTCAGT |
| LOC108352208 | GAGGTTCAGGAAGAGCACCAG | AACAGGAGCTACCCACCAAGAG |
| LOC103694103 | GGCTTCAAAAGGCTGTGGTG | GTGGAGGTGTGTCAGCAGTT |
| LOC103693799 | TGATGAACAGGGGCATCTGAA | GCACACCCTACATCTCAAGCA |
| GPX4 | CAAAGTCCTAGGAAGCGCCC | GCATCGTCCCCACTTACACA |
| SLC7A11 | GTGTTTGCTGTCTCCAGGTTAT | TCTTTAGAGTCTTCTGGTACAACTT |
| SLC1A5 | GGGCTGTAGGATGACAGGAAT | GTCCCGAAAGCTGTAGCCAG |
| PTGS2 | ACGTGTTGACGTCCAGATCA | ACGTGGGGAGGGTAGATCAT |
FIGURE 1The rat model of CCI exhibits persistent mechanical and thermal hypersensitivities and accompanied by long-term memory deficit. (A): The flowchart of the establishment of the CCI-induced memory impairment rat model. (B): 50% paw withdrawal thresholds (PWTs) of the left hind paw of sham and CCI-induced memory impairment rats. (C): 50% paw withdrawal latencies (PWLs) of the left hind paw of sham and CCI-induced memory impairment rats. (D,E): Mean withdrawal scores and duration of cold hyperalgesia. (F): %spontaneous alternation in the Y maze test. (G): Recognition index in the NOR test. n = 6–9 rats/group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs sham group. Student’s t and ANOVA tests were used for comparisons.
The detail of the top 20-upregulated DEmRNAs.
| Upregulated gene name | Gene ID | Location | Log2 (fold change) (CCI/Sham) |
|
|---|---|---|---|---|
| LOC100911730 | 64315 | 196564744–196568753 | 5.78102698 | 0.01230071 |
| Tsen34l1 | 100909510 | 63242432–63250265 | 5.57491881 | 0.00877734 |
| Six2 | 366542 | 8974859–8981345 | 4.97072558 | 0.02731944 |
| LOC100912573 | 293749 | 208243561–208255400 | 4.5235508 | 0.03086266 |
| Yipf7 | 364147 | 38571045–38599070 | 4.3849271 | 0.03951931 |
| Adam5 | 498654 | 67223095–67298733 | 3.96381527 | 0.02477011 |
| Fkbp6 | 288597 | 21318251–21390350 | 3.25554386 | 0.00830697 |
| Tnnt1 | 171409 | 69306362–69316721 | 3.20696783 | 0.00022016 |
| RGD1562652 | 499402 | 2632898–2635694 | 2.64444974 | 0.0097335 |
| LOC103690118 | 83836 | 839788–883946 | 2.63854731 | 0.0103477 |
| LOC100909392 | 292944 | 12698107–12775561 | 2.60782392 | 0.0000251 |
| Ces1d | 113902 | 13873490–13912035 | 2.48941746 | 0.04505145 |
| Tbcb | 292777 | 85477639–85483488 | 2.35883642 | 0.0000165 |
| Phykpl | 100169747 | 35839965–35863631 | 2.25983594 | 0.0000411 |
| Prg4 | 289104 | 62487257–62504657 | 2.25639342 | 0.02979234 |
| LOC100912228 | 24604 | 78881294–78888495 | 2.24267013 | 4.61E-08 |
| LOC100911186 | 140547 | 194895036–194903863 | 2.20391882 | 0.00244014 |
| Pnpla2 | 361676 | 196552723–196557805 | 2.1788874 | 0.000012 |
| Hprt1 | 24465 | 132736175–132768149 | 2.08657003 | 0.00037877 |
| LOC685933 | 685933 | 236603597–236685859 | 2.02708822 | 0.03049839 |
The detail of the top 20-downregulated DEmRNAs.
| Down-regulated gene name | Gene ID | Location | Log2 (fold change) (CCI/Sham) |
|
|---|---|---|---|---|
| LOC685716 | 685716 | 55279853–55326753 | −5.2745565 | 0.00383337 |
| Slc24a5 | 311387 | 112319305–112339231 | −5.140615 | 0.01109464 |
| LOC100912034 | 64199 | 32023003–32028443 | −4.9495918 | 0.0065692 |
| P2ry10 | 317219 | 72121558–72207174 | −3.8438431 | 0.03376527 |
| LOC100910278 | 64040 | 79505738..79522539 | -3.6968195 | 0.00012598 |
| LOC102557478 | 102557478 | 68443437–68505774 | −3.2566427 | 0.01336716 |
| Mrpl53 | 362388 | 115615329–115616219 | −2.6079781 | 1.58E-05 |
| NEWGENE_1308196 | 301352 | 40125352–40136189 | −2.596599 | 0.00038693 |
| Lipg | 291437 | 68514923–68536105 | −2.5262274 | 0.03772631 |
| LOC100911814 | 309312 | 227883247..227962119 | −2.4137944 | 0.02360257 |
| Gimap4 | 286938 | 77636401–77643315 | −2.3785594 | 0.0379737 |
| Gdf7 | 252833 | 31171495–31182447 | −2.3596019 | 0.04450489 |
| RT1-T24-1 | 361787 | 2761541–2774749 | -2.2627501 | 0.0416867 |
| Kif14 | 360849 | 47926975–47990598 | -2.2606806 | 0.03106551 |
| Mgat2 | 94273 | 87656360–87658849 | −2.1608588 | 0.00867277 |
| LOC100909709 | 89821 | 96263322–96314197 | −2.1581355 | 0.00638393 |
| Rpl39l | 497860 | 5455712–5459828 | −2.0308892 | 0.02228026 |
| Romo1 | 679572 | 144659709–144661310 | −2.0164828 | 0.00390799 |
| LOC100911994 | 312083 | 31484424–31585617 | −1.9809055 | 0.00040545 |
| RT1-Db1 | 294270 | 4548664–4558237 | −1.9316996 | 0.00064276 |
The detail of the top 20-upregulated DElncRNAs.
| Upregulated gene | Gene ID | Location | Log2 Fold change (CCI/Sham) |
|
|---|---|---|---|---|
| ENSRNOT00000076561 | — | 5.78512442 | 0.01730266 | |
| ENSRNOT00000077876 | — | 2.20373049 | 0.02111258 | |
| ENSRNOT00000079282 | — | 2.09798552 | 0.04796722 | |
| ENSRNOT00000081463 | — | 6.06317183 | 0.04165964 | |
| ENSRNOT00000083718 | — | 2.66877138 | 0.03800823 | |
| ENSRNOT00000084042 | — | 3.53248432 | 0.00746108 | |
| ENSRNOT00000086466 | — | 2.90999256 | 0.00483471 | |
| ENSRNOT00000088572 | — | 1.63653171 | 0.00185723 | |
| ENSRNOT00000088984 | — | 3.06189614 | 0.04935497 | |
| ENSRNOT00000089993 | — | 0.94690101 | 0.01452598 | |
| ENSRNOT00000092488 | — | 7.59302524 | 0.00000197 | |
| NR_126572.1 | 102554851 | 107727772–107739795 | 2.04684063 | 0.03806143 |
| TCONS_00000046 | — | 3.67510588 | 4.54E-10 | |
| TCONS_00000063 | — | 3.6221488 | 0.00521153 | |
| TCONS_00000066 | — | 5.01538596 | 0.0000116 | |
| TCONS_00000072 | — | 3.72144139 | 7.83E-08 | |
| TCONS_00003409 | — | 6.19777226 | 0.03438166 | |
| TCONS_00004570 | — | 5.26965975 | 0.00385247 | |
| TCONS_00007059 | — | 1.97880803 | 0.00534686 | |
| TCONS_00008373 | — | 6.35884856 | 0.0057876 | |
The detail of the top 20-downregulated DElncRNAs.
| Down-regulated gene name | Gene ID | Location | Log2 (fold change) (CCI/Sham) |
|
|---|---|---|---|---|
| ENSRNOT00000079308 | — | −6.4901256 | 0.00389627 | |
| ENSRNOT00000080318 | — | −3.2237543 | 0.04966201 | |
| ENSRNOT00000080624 | — | −5.5762886 | 0.0226858 | |
| ENSRNOT00000081988 | — | −5.4100888 | 0.00722821 | |
| ENSRNOT00000083218 | — | −1.3429282 | 0.00913697 | |
| ENSRNOT00000083980 | — | −4.8410086 | 0.02553616 | |
| ENSRNOT00000085297 | — | −3.4793701 | 0.00869084 | |
| ENSRNOT00000085430 | — | −1.5983594 | 0.00029936 | |
| ENSRNOT00000086000 | — | −5.2736508 | 0.00650296 | |
| ENSRNOT00000087909 | — | −0.6072032 | 0.00820781 | |
| ENSRNOT00000090624 | — | −0.9477649 | 0.03438361 | |
| NR_110678.1 | 100910558 | 96976181–97014187 | −1.9759649 | 0.02172322 |
| TCONS_00000049 | — | — | −1.6223783 | 0.00036462 |
| TCONS_00000050 | — | — | −0.6466528 | 0.02698395 |
| TCONS_00002534 | — | — | −1.3421975 | 4.69E-08 |
| TCONS_00002535 | — | — | −0.7819754 | 0.00362422 |
| TCONS_00002540 | — | — | −0.7632558 | 0.00609918 |
| TCONS_00002547 | — | — | −2.4841896 | 0.02406492 |
| TCONS_00002551 | — | — | −0.9798316 | 0.00531827 |
| TCONS_00002552 | — | — | −1.6084354 | 0.00000503 |
FIGURE 2Randomly validation of DEGs from RNA-Seq via qRT-PCR. (A): The expression of five randomly downregulated DEmRNAs via qRT-PCR. (B): The expression of four randomly upregulated DEmRNAs via qRT-PCR. (C): The expression of five randomly downregulated DElncRNAs via qRT-PCR. (D): The expression of three randomly upregulated DElncRNAs via qRT-PCR. n = 3–6 rats/group. *p < 0.05, **p < 0.01, ***p < 0.001 vs sham group. Student’s t test was used for comparisons.
FIGURE 3GO analysis of DEmRNAs. (A,C,E): The top 10 significant biological process, cellular components, and molecular functions of downregulated DEmRNAs. (B,D,F): The top 10 significant biological processes, cellular components, and molecular functions of upregulated DEmRNAs.
FIGURE 4KEGG analysis of DEGs. (A,B): The top 10 enriched pathways of downregulated DEmRNAs and DElncRNAs. (C,D): The top 10 enriched pathways of upregulated DEmRNAs and DElncRNAs.
FIGURE 5ATF3 expression of Hippocampus CA1 area increased in the CCI-induced memory impairment rat model. (A): Representative immunofluorescence image indicating ATF3 antibody staining of the hippocampus CA1 (A,B) from sham and CCI-induced hippocampus. DAPI (blue) was used for cell nucleus labeling. NeuN (red) was used for neuron labeling. Green was used for the ATF3 positive area. GFAP (red) was used for astrocyte labeling. (C): Summary of ATF3 positively stained neurons per observation area in the hippocampus from two groups. (D): Validation of ATF3 protein expression in the hippocampus via western blot. n = 4–6 rats/group, *p < 0.05 vs sham group. The student’s t test was used for comparisons.
FIGURE 6Validation of ferroptosis-associated gene markers. (A): validation of gene marker mRNA levels in the hippocampus for ferroptosis by qRT-PCR. (B,C): Validation of GPX4 and SLC7A11 protein expression level in the hippocampus by western blot. n = 3–6 rats/group, *p < 0.05 vs sham group. The student’s t test was used for comparisons.
FIGURE 7Iron overload, lipid peroxidation, and neuronal damage in the hippocampus of the CCI-induced memory impairment rat model. (A,D): Compared with sham rats, the number of Nissl positive bodies in the hippocampus of CCI-induced memory impairment was decreased, and the morphology of Nissl positive bodies was obviously changed. (B): DAB-enhanced Perls stain showed Perls positive iron deposits in the hippocampus of CCI-induced memory impairment rat model. (C): Iron content in hippocampus and plasma were significantly increased in the hippocampus of CCI-induced memory impairment. (E–H): showing the lipid peroxidation in the hippocampus of CCI-induced memory impairment as the following results: significantly increased ROS level (E) and MDA content (F), significantly downregulated SOD activity (G) and GSH content (H) via corresponding detection kits. n = 3–6 rats/group, *p < 0.05, **p < 0.01 vs sham group. The student’s t test was used for comparisons.
FIGURE 8Ferrostatin-1 significantly reversed the improved CCI-induced hyperalgesia and memory impairment. (A): Representative scatter diagram showing the 50% paw withdrawal thresholds (PWTs) of the left hind paw in these above groups. (B): Representative scatter diagram showing the 50% paw withdrawal latencies (PWLs) of the left hind paw in these above groups. (C,D): Representative scatter diagram showing mean withdrawal scores and duration of cold hyperalgesia in these above groups. (E): Representative scatter diagram showing %spontaneous alternation of Y maze test in these above groups. (F): Representative scatter diagram showing the recognition index of NOR test (Day 21 after CCI) in these above groups. n = 6 rats/group. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs sham group or CCI + Fer-1 group. One-way ANOVA test was used for comparisons.
FIGURE 9Ferrostatin-1 significantly inhibited the ferroptotic damage. (A,B): Representative scatter diagram showing the iron content of hippocampus and plasma in these above groups. (C–F): Representative scatter diagram showing the levels of ROS (C), MDA (D), GSH (E), and SOD (F) of hippocampus in these above groups. (G–J): Representative scatter diagram showing validation of gene marker mRNA levels in the hippocampus for ferroptosis. n = 3–6 rats/group. *p < 0.05, **p < 0.01, ***p < 0.001 vs sham group or CCI + Fer-1 group. One-way ANOVA test was used for comparisons.